| Literature DB >> 33531151 |
José Antonio Caminero Luna1, Guillermo Pérez Mendoza2, Felipe Rodríguez de Castro2.
Abstract
Drug-resistant tuberculosis, especially those with resistance to rifampicin (RR-TB), has become one of the main obstacles to achieving the dream of eradicating tuberculosis. Furthermore, it is necessary to combine three or four different drugs in the attempt to cure TB, however, unfortunately, there are few available that can be considered genuinely effective. Fortunately, the notable worldwide increase in RR-TB in recent years has led to the investment of resources in the development of new drugs for TB, and other drugs investigated for other diseases have been successfully tested on TB. This has resulted in a clear change in the clinical management of these patients over the last 3-4 years, and it is now easier to design therapeutic regimens and achieve higher success rates. All these changes are updated in this review.Entities:
Keywords: Drug-resistant tuberculosis; Extensively drug-resistant tuberculosis; MDR-TB; Multi-drug resistant tuberculosis; TB extensamente fármaco resistente; TB-MDR; TB-XDR; Tratamiento; Treatment; Tuberculosis; Tuberculosis con resistencia a fármacos; Tuberculosis multi-resistente; XDR-TB
Mesh:
Substances:
Year: 2021 PMID: 33531151 DOI: 10.1016/j.medcli.2020.08.018
Source DB: PubMed Journal: Med Clin (Barc) ISSN: 0025-7753 Impact factor: 1.725